Phase 2Suspended
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
A Phase 2, Randomized, Open Label Study to Evaluate Efficacy, Safety, and Tolerability of CA102N Combined With Trifluridine/Tipiracil (TAS-102) Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer (mCRC) Who Failed the Standard Treatment
- Sponsor
- Holy Stone Healthcare Co., Ltd (Industry)
- Enrollment
- 100 planned
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- CA102N; TAS-102; Bevacizumab
- Ages
- adults, older adults
- Registry
- NCT06039202
Full record on ClinicalTrials.gov
From the registry
HS-CA102N-103 is a Phase 2, randomized, open label study to evaluate efficacy, safety, and tolerability of CA102N combined with trifluridine/tipiracil (TAS-102) compared to bevacizumab combined with TAS-102 in subjects with metastatic colorectal cancer (mCRC) who failed the standard treatment (for eg, cancer that has relapsed after or is refractory to fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy).
Primary outcomes
- To evaluate the efficacy of CA102N in combination with trifluridine/tipiracil (TAS-102) by progression free survival (PFS) rate.
- Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered